Use of recommended medications after myocardial infarction in Austria

European Journal of Epidemiology

Volumn 23, Issue 2, 2008, Pages 153-162

  Winkelmayer, Wolfgang C ^a   Bucsics, Anna E ^b   Schautzer, Alexandra ^c   Wieninger, Peter ^b   Pogantsch, Michaela ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Hauptverband der Osterreichischen Sozialversicherungstrager   (Austria)

^c Steiermarkische Gebietskrankenkasse   (Austria)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; Beta blockers; Myocardial infarction; Secondary prevention; Statins

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; STATIN;

ADULT; AGED; ARTICLE; AUSTRIA; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OUTPATIENT; PRESCRIPTION; SECONDARY PREVENTION;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AUSTRIA; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATIONAL HEALTH PROGRAMS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RECURRENCE;

EID: 38649113547     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-007-9212-4     Document Type: Article

References (40)

1. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999;353:1547-57.
2. Rosamond WD, Chambless LE, Folsom AR, Cooper LS, Conwill DE, Clegg L, Wang CH, Heiss G. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 1998;339:861-7.
3. Burwen DR, Galusha DH, Lewis JM, Bedinger MR, Radford MJ, Krumholz HM, Foody JM. National and state trends in quality of care for acute myocardial infarction between 1994-1995 and 1998-1999: the medicare health care quality improvement program. Arch Intern Med 2003;163:1430-9.
4. Tunstall-Pedoe H, Vanuzzo D, Hobbs M, Mahonen M, Cepaitis Z, Kuulasmaa K, Keil U. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet 2000;355:688-700.
5. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet 2002;360:752-60.
6. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan in acute myocardial infarction trial I. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906.
7. Winkelmayer WC, Fischer MA, Schneeweiss S, Levin R, Avorn J. Angiotensin inhibition after myocardial infarction: does drug class matter? J Gen Int Med 2006;21:1242-7.
8. Tsevat J, Kuntz KM, Orav EJ, Weinstein MC, Sacks FM, Goldman L. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 2001;141:727-34.
9. Goldman L, Sia ST, Cook EF, Rutherford JD, Weinstein MC. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med 1988;319:152-7.
10. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991;265:1145-51.
11. Malik IS, Bhatia VK, Kooner JS. Cost effectiveness of ramipril treatment for cardiovascular risk reduction. Heart 2001;85:539-43.
12. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, Julian D, Lengyel M, Neumann FJ, Ruzyllo W, Thygesen C, Underwood SR, Vahanian A, Verheugt FW, Wijns W. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The task force on the management of acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2003;24:28-66.
13. Giugliano RP, Braunwald E. 2004 ACC/AHA guideline for the management of patients with STEMI: the implications for clinicians. Nat Clin Pract Cardiovasc Med 2005;2:114-5.
14. Pollack CV Jr, Gibler WB. 2000 ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a practical summary for emergency physicians. Ann Emerg Med 2001;38:229-40.
15. O'Connor GT, Quinton HB, Traven ND, Ramunno LD, Dodds TA, Marciniak TA, Wennberg JE. Geographic variation in the treatment of acute myocardial infarction: the Cooperative Cardiovascular Project. JAMA 1999;281:627-33.
16. Bradley EH, Herrin J, Mattera JA, Holmboe ES, Wang Y, Frederick P, Roumanis SA, Radford MJ, Krumholz HM. Hospital-level performance improvement: beta-blocker use after acute myocardial infarction. Med Care 2004;42:591-9.
17. Krumholz HM, Chen J, Rathore SS, Wang Y, Radford MJ. Regional variation in the treatment and outcomes of myocardial infarction: investigating New England's advantage. Am Heart J 2003;146:242-9.
18. Epstein AM. Rolling down the runway: the challenges ahead for quality report cards. JAMA 1998;279:1691-6.
19. Lambie L, Mattke S. Selecting indicators for the quality of cardiac care at the health systems level in OECD countries. OECD Health Technical Papers No. 14 2004 available at http://www.oecd.org/ ;els/health/technicalpapers.
20. Tran CT, Lee DS, Flintoft VF, Higginson L, Grant FC, Tu JV, Cox J, Holder D, Jackevicius C, Pilote L, Tanser P, Thompson C, Tsoi E, Warnica W, Wielgosz A. CCORT/CCS quality indicators for acute myocardial infarction care. Can J Cardiol 2003;19:38-45.
21. Krumholz HM, Radford MJ, Wang Y, Chen J, Heiat A, Marciniak TA. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA 1998;280:623-9.
22. Seddon ME, Ayanian JZ, Landrum MB, Cleary PD, Peterson EA, Gahart MT, McNeil BJ. Quality of ambulatory care after myocardial infarction among Medicare patients by type of insurance and region. Am J Med 2001;111:24-32.
23. Barron HV, Michaels AD, Maynard C, Every NR. Use of angiotensin- converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2. J Am Coll Cardiol 1998;32:360-7.
24. Gislason GH, Abildstrom SZ, Rasmussen JN, Rasmussen S, Buch P, Gustafsson I, Friberg J, Gadsboll N, Kober L, Stender S, Madsen M, Torp-Pedersen C. Nationwide trends in the prescription of beta-blockers and angiotensin- converting enzyme inhibitors after myocardial infarction in Denmark, 1995-2002. Scand Cardiovasc J 2005;39:42-9.
25. Jullien G, Mosnier M, Danchin N. Évolution de la prescription de prévention secondaire chez les coronariens après revascularisation: enquête ANCOR [Evolution of secondary prevention medication prescriptions after myocardial revascularisation: the ANCOR survey]. Ann Cardiol Angeiol (Paris) 2005;54:184-9.
26. van der Elst ME, Bouvy ML, de Blaey CJ, de Boer A. Preventive drug use in patients with a history of nonfatal myocardial infarction during 12-year follow-up in The Netherlands: a retrospective analysis. Clin Ther 2005;27:1806-14.
27. EUROASPIRE A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European action on secondary prevention through intervention to reduce events. Eur Heart J 1997;18:1569-82.
28. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-72.
29. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European action on secondary prevention by intervention to reduce events. Lancet 2001;357:995-1001.
30. Gouya G, Reichardt B, Ohrenberger G, Wolzt M. Survival of patients discharged after acute myocardial infarction and evidence-based drug therapy. Eur J Epidemiol 2007;22:145-9.
31. Bennett CL, Schwarz B, Marberger M. Health care in Austria. Universal access, national health insurance, and private health care. JAMA 1993;269:2789-94.
32. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 2004;148:99-104.
33. Pilote L, Beck CA, Karp I, Alter D, Austin P, Cox J, Humphries K, Jackevicius C, Richard H, Tu JV. Secondary prevention after acute myocardial infarction in four Canadian provinces, 1997-2000. Can J Cardiol 2004;20:61-7.
34. Rasmussen JN, Gislason GH, Abildstrom SZ, Rasmussen S, Gustafsson I, Buch P, Friberg J, Kober L, Torp-Pedersen C, Madsen M, Stender S. Statin use after acute myocardial infarction: a nationwide study in Denmark. Br J Clin Pharmacol 2005;60:150-8.
35. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
36. Ganz DA, Kuntz KM, Jacobson GA, Avorn J. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med 2000;132:780-7.
37. Lopez-Sendon J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The task force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004a;25:1454-70.
38. Lopez-Sendon J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004b;25:1341-62.
39. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001;154:854-64.
40. Solomon DH, Schneeweiss S, Glynn RJ, Levin R, Avorn J. Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med 2003;115:715-20.